<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1840">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368351</url>
  </required_header>
  <id_info>
    <org_study_id>DPHID-UniRoma05</org_study_id>
    <nct_id>NCT04368351</nct_id>
  </id_info>
  <brief_title>Bacteriotherapy in the Treatment of COVID-19</brief_title>
  <acronym>BACT-ovid</acronym>
  <official_title>Evaluation of the Impact of Bacteriotherapy in the Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In light of its high morbidity and mortality, COronaVIrus Disease 19 (COVID-19) pandemic
      spread is considered an unprecedented global health challenge.

      Given the very limited therapeutic options available against Severe Acute Respiratory
      Syndrome - CoronaVirus-2 (SARS-CoV-2) epidemic at this time, the evaluation of new resources,
      designed in the first instance for other pathologies but potentially active against COVID-19,
      represents a priority in clinical research.

      This is an observational, retrospective, non-profit study on the adjuvant use of
      bacteriotherapy in the early control of disease progression in patients affected by COVID-19
      and treated with the current standard of care on the basis of the interim guidelines of the
      Italian Society of Infectious and Tropical Diseases.

      The main purpose of the study is to evaluate the effectiveness of bacteriotherapy in reducing
      the clinical impact of acute diarrhea, containing the progression of COVID-19 and preventing
      the need for hospitalization in intensive care units.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Italy was the first European country hit by the severe outbreak of the SARS-CoV-2 epidemic
      emerged from China, with a high morbidity and associated mortality.

      Given the limited treatment options currently available, the search for resources capable of
      improving disease outcomes is fundamental for the management of patients

      Systemic inflammation related to COVID-19, dietary changes, and use of antibiotics are all
      variables that contribute to changes in the gut microbiota with significant impact on the
      disease outcomes. Probiotic supplementation can help to correct these issues.

      Moreover some strains of lactobacilli and bifidobacteria inhibit influenza virus, rhinovirus,
      respiratory syncytial virus, adenovirus, and pneumovirus .
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>delta of time of disappearance of acute diarrhea</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups. Acute diarrhea was defined as a stool with increased water content, volume, or frequency that lasts less than 14 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta in the number of patients requiring orotracheal intubation despite treatment</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta of crude mortality</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta of length of stay for patients in hospital</measure>
    <time_frame>21 days</time_frame>
    <description>Comparison between the two groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>COVID</condition>
  <condition>Pneumonia</condition>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <description>Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bacteriotherapy</arm_group_label>
    <description>Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SivoMixx (200 billion)</intervention_name>
    <description>Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM nÂ°... : bacterial strain identification code)</description>
    <arm_group_label>bacteriotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>bacteriotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <description>dose: 200 mg, 1 cp x 2 / day</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>bacteriotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic patients affected by COVID-19 admitted to Policlinico Umberto I, University of
        Rome &quot;Sapienza&quot; (Italy), between March 14, 2020 and April 4, 2020.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 diagnosis

          -  symptomatic COVID-19

          -  hospitalization in infectious diseases wards

        Exclusion Criteria:

          -  Pregnant

          -  hospitalization in Intensive Care Unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriella d'Ettorre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome Sapienza - Policlinico Umberto I Rome (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Public Heath and Infectious Diseases. University of Rome &quot;Sapienza&quot; (Italy)</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J, Wang H, Yu L, Huang H, Qiu Y, Wei G, Fang Q, Zhou J, Sheng J, Liang T, Li L. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(1):0. Chinese.</citation>
    <PMID>32096367</PMID>
  </results_reference>
  <results_reference>
    <citation>Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015 May 15;60 Suppl 2:S108-21. doi: 10.1093/cid/civ177. Review.</citation>
    <PMID>25922396</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang X, Hou X, Tang L, Jiang Y, Ma G, Li Y. A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection. Appl Microbiol Biotechnol. 2016 Sep;100(17):7457-69. doi: 10.1007/s00253-016-7424-9. Epub 2016 Mar 28.</citation>
    <PMID>27020282</PMID>
  </results_reference>
  <results_reference>
    <citation>Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes Metab Syndr. 2020 Jul - Aug;14(4):367-382. doi: 10.1016/j.dsx.2020.04.015. Epub 2020 Apr 16.</citation>
    <PMID>32334392</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Giancarlo Ceccarelli</investigator_full_name>
    <investigator_title>MD, PhD, MSc</investigator_title>
  </responsible_party>
  <keyword>COVID-19 pneumonia</keyword>
  <keyword>gut-lung axis</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

